GT Biopharma, Inc. (GTBP) Stock Score, Valuation & Financial Research

GT Biopharma, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for GTBP

GT Biopharma, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 6.37. These figures are a research snapshot, not a buy or sell recommendation.

What GT Biopharma, Inc. does

GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

GT Biopharma is a clinical-stage immuno-oncology company that generates value through the research and development of its proprietary TriKE platform. The company does not currently generate commercial revenue from product sales, as its therapeutic candidates are in clinical development stages, and it relies on capital raises and licensing agreements to fund operations.

Products and services

The company develops TriKE (Tri-specific Killer Engager) technology, a platform designed to enhance the ability of natural killer (NK) cells to target and destroy cancer cells in various hematologic malignancies and solid tumors.

Brands and product families

TriKE — Proprietary NK cell engager platform technology. Source

Customer types

Clinical trial patients.

Suppliers, materials and equipment

Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials; specific supplier names are not disclosed. Source

Business relationships and partnerships

University of Minnesota — The company holds an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using the TriKE technology platform. Source

Business strengths to evaluate

Proprietary TriKE platform technology Source

Business risks and research considerations

History of operating losses and dependence on external financing Source
Material weakness in internal controls over financial reporting Source

Sources: Company research source · TriKE · University of Minnesota · Material weakness in internal controls over financial reporting

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

GTBP financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:: Not currently available
Stored price:: USD 6.37
Market capitalization:: 8.04M (currency not supplied)
Revenue:: USD 0.00
Net income:: USD -22.08M
Free cash flow:: USD -12.91M
Cash:: USD 4.96M
Total debt:: USD 0.00
EPS:: USD -104.00

What stands out

Free cash flow is USD -12.91M, negative for the stored period.
The balance sheet shows USD 4.96M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

Cash exceeds debt by USD 4.96M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for GTBP

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

How long can GTBP fund negative free cash flow using its current cash position before it may need more debt or new shares?
How is GTBP likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
What specifically needs to improve for GTBP to reach sustainable profitability?
What does the current fundamental change risk warning mean for the reliability or interpretation of GTBP's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research GTBP

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.